The Experts below are selected from a list of 79167 Experts worldwide ranked by ideXlab platform
Gwendolyn E Niebler - One of the best experts on this subject based on the ideXlab platform.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
Richard H Weisler - One of the best experts on this subject based on the ideXlab platform.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
Timothy H. Rainer - One of the best experts on this subject based on the ideXlab platform.
-
the normal ranges of Cardiovascular Parameters measured using the ultrasonic cardiac output monitor
Physiological Reports, 2017Co-Authors: Giles N Cattermole, P Mia Y Leung, Stewart Siuwa Chan, Cangel Pui Yee Chan, Grace Ho, Brendan E Smith, Timothy H. Rainer, Colin A. GrahamAbstract:Abstract The ultrasonic cardiac output monitor (USCOM) is a noninvasive transcutaneous continuous wave Doppler method for assessing hemodynamics. There are no published reference ranges for normal values in adults (aged 18–60 years) for this device. This study aimed to (1) measure Cardiovascular indices using USCOM in healthy adults aged 18–60 years; (2) combine these data with those for healthy children (aged 0–12), adolescents (aged 12–18), and the elderly (aged over 60) from our previously published studies in order to present normal ranges for all ages, and (3) establish normal ranges of USCOM‐derived variables according to both weight and age. This was a population‐based cross‐sectional observational study of healthy Chinese subjects aged 0.5–89 years in Hong Kong. USCOM scans were performed on all subjects, to produce measurements including stroke volume, cardiac output, and systemic vascular resistance. Data from previously published studies (children, adolescents, and the elderly) were included. Normal ranges were defined as lying between the 2.5th and 97.5th percentiles. A total of 2218 subjects were studied (mean age = 16.4, range = 0.5–89; 52% male). From previous studies, 1197 children (aged 0–12, 55% male), 590 adolescents (aged 12–18, 49% male), and 77 elderly (aged 60–89, 55% male) were included. New data were collected from 354 adults aged 18–60 (47% male). Normal ranges are presented according to age and weight. We present comprehensive normal ranges for hemodynamic Parameters obtained with USCOM in healthy subjects of all ages from infancy to the elderly.
-
the normal ranges of Cardiovascular Parameters in children measured using the ultrasonic cardiac output monitor
Critical Care Medicine, 2010Co-Authors: Giles N Cattermole, P Mia Y Leung, Stewart Siuwa Chan, Colin A. Graham, Timothy H. RainerAbstract:Objective: The Ultrasonic Cardiac Output Monitor is a noninvasive method of hemodynamic assessment and monitoring in critically ill patients. There are no published reference ranges for normal values in children for this device. This study aimed to establish normal ranges for Cardiovascular indices measured using Ultrasonic Cardiac Output Monitor in children aged 0–12 yrs old and to assess interobserver reliability. Design: This was a population-based cross-sectional observational study. Setting: Schools and kindergartens in Hong Kong. Subjects: Chinese children aged up to 12 yrs old. Interventions: Two operators performed Ultrasonic Cardiac Output Monitor scans on each child together with standard oscillometric measurement of blood pressure and heart rate. Software intrinsic to the Ultrasonic Cardiac Output Monitor device produces values for stroke volume, cardiac output, and systemic vascular resistance. For each parameter, normal ranges were defined as lying between the 2.5th and 97.5th percentiles. Interobserver reliability was assessed with Bland-Altman plots, coefficients of variation, and intraclass correlation. Measurements and Main Results: A total of 1,197 Chinese children (55% boys) were scanned. Normal ranges of values for cardiac output, stroke volume, and systemic vascular resistance indices are presented. Interobserver reliability for Ultrasonic Cardiac Output Monitor was superior to that for standard blood pressure and heart rate measurement. Conclusions: This large study presents normal values for Cardiovascular indices in children using the Ultrasonic Cardiac Output Monitor with good interobserver reliability.
Lenard A Adler - One of the best experts on this subject based on the ideXlab platform.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
-
short term effects of lisdexamfetamine dimesylate on Cardiovascular Parameters in a 4 week clinical trial in adults with attention deficit hyperactivity disorder
The Journal of Clinical Psychiatry, 2009Co-Authors: Lenard A Adler, Richard H Weisler, Mohamed Hamdani, David W Goodman, Gwendolyn E NieblerAbstract:Objective: To evaluate the short-term impact of lisdexamfetamine dimesylate on Cardiovascular Parameters in adults with attention-deficit/ hyperactivity disorder (ADHD). Method: Medically healthy adults (18―55 years of age) with DSM-IV-TR―defined ADHD were randomly assigned to placebo or 30, 50, or 70 mg/d of lisdexamfetamine dimesylate for 4 weeks between May and November 2006. Electrocardiograms, systolic and diastolic blood pressure, and pulse were assessed pretreatment and weekly thereafter. Results: There were no significant differences for mean systolic or diastolic blood pressure in any lisdexamfetamine dimesylate dose group versus placebo. Changes in pulse from baseline to endpoint were 0.0, 2.8, 4.2, and 5.2 bpm in the placebo and lisdexamfetamine dimesylate 30, 50, and 70 mg/d groups, respectively (P<.05, all lisdexamfetamine dimesylate groups vs placebo). Post hoc pulse outliers (pulse ≥ 100 bpm; any 1 event) ranged from 3.3% to 8.5% of subjects in the lisdexamfetamine dimesylate groups, and no subjects in the placebo group were pulse outliers (P < .05 for lisdexamfetamine dimesylate 50 mg vs placebo only). There were no clinically meaningful electrocardiogram abnormalities. Overall, 8.3% (35/420; safety population) of subjects had treatment-emergent Cardiovascular adverse events, and 1.7% (7/420) withdrew from the study because of Cardiovascular complaints. Cardiovascular adverse events with lisdexamfetamine dimesylate in these medically healthy adults were generally mild to moderate in severity. Conclusions: Lisdexamfetamine dimesylate had limited short-term effects on heart rate, blood pressure, and electrocardiogram Parameters that were of minimal clinical concern. These findings support the relative safety of lisdexamfetamine dimesylate. However, considering the potential of outliers, it is advisable to monitor Cardiovascular Parameters in stimulant-treated patients. Interpretation of these findings is limited to patients with no preexisting cardiac conditions who are taking their medication as prescribed.
Stephen J Leslie - One of the best experts on this subject based on the ideXlab platform.
-
reflexology has an acute immediate haemodynamic effect in healthy volunteers a double blind randomised controlled trial
Complementary Therapies in Clinical Practice, 2012Co-Authors: Jenny Jones, Pat Thomson, William Lauder, Kate Howie, Stephen J LeslieAbstract:Abstract Reflexologists claim that massage to specific points of the feet increases blood supply to internal organs. This study measured changes in Cardiovascular Parameters in subjects receiving reflexology to areas of their feet thought to correspond to the heart (intervention) compared with other areas which are not (control). Method 16 reflexology-naive healthy volunteers received an active and control reflexology treatment in an RCT, double-blind repeated measures study. Main outcome measures ‘Beat-to-beat' continuous measurement of selected Cardiovascular Parameters, State Anxiety Inventory. Results Cardiac index decreased significantly in the intervention group during left foot treatment (LFT) (baseline mean 2.6; standard deviation (SD) 0.75; 95% CI ± 0.38 vs. LFT mean 2.45; SD 0.68; CI 0.35), effect size ( p = 0.035, omega squared effect ( w 2) = 0.002; w = 0.045). Conclusion Reflexology massage applied to the upper part of the left foot may have a modest specific effect on the cardiac index of healthy volunteers.